Tretinoin with standard drugs for untreated acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding tretinoin (a form of vitamin A) to the standard combination of azacitidine and venetoclax can help people with newly diagnosed acute myeloid leukemia (AML) who have not yet received treatment. The goal is to see if this triple therapy can improve remission rates and overall outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a new diagnosis of acute myeloid leukemia (AML), but not the APL subtype.
- You must not have had any previous leukemia treatment, except for hydroxyurea (to lower white blood cell count) or leukapheresis (a filtering procedure).
- Your total white blood cell count must be 25,000 or lower.
- You must be between 18 and 60 years old.
- Your liver and kidney function must be within acceptable limits, and your heart must be functioning well enough.
- You must be willing to sign a consent form agreeing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—for people with acute myeloid leukemia (AML) who cannot have intensive chemotherapy, or whose leukemia has returned after treatment. The goal is to see if this combination helps control the leukemia with manageable side effects.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.